Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice
Mutations in FKRP impair glycosylation of alpha-dystroglycan, leading to muscular dystrophy. Here, the authors show that oral administration of ribitol increases dystropglycan glycosylation and ameliorates symptoms of muscular dystrophy in FKRP-deficient mouse models.
Main Authors: | Marcela P. Cataldi, Peijuan Lu, Anthony Blaeser, Qi Long Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-05990-z |
Similar Items
-
ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice
by: Marcela P. Cataldi, et al.
Published: (2020-06-01) -
NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes
by: Carolina Ortiz-Cordero, et al.
Published: (2021-01-01) -
Overexpression of Mutant FKRP Restores Functional Glycosylation and Improves Dystrophic Phenotype in FKRP Mutant Mice
by: Jason D. Tucker, et al.
Published: (2018-06-01) -
Distinct expression of functionally glycosylated alpha-dystroglycan in muscle and non-muscle tissues of FKRP mutant mice.
by: Anthony Blaeser, et al.
Published: (2018-01-01) -
ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan
by: Isabelle Gerin, et al.
Published: (2016-05-01)